

CLAIMS

1. A crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting peaks at two or more angles selected from the group consisting of 10.5° , 19.6° , 23.7° , 26.2° , and 31.2° as a diffraction angle ($2\theta \pm 0.1^\circ$) in powder X-ray diffraction.

2. The crystal according to claim 2, exhibiting peaks at angles of 10.5° , 19.6° , 23.7° , 26.2° , and 31.2° as a diffraction angle ($2\theta \pm 0.1^\circ$) in powder X-ray diffraction.

3. The crystal according to claim 1 or 2, exhibiting an endothermic peak determined by thermogravimetry-differential thermal analysis at a temperature of around 245°C .

4. The crystal according to any of claims 1 to 3, which shows, in single-crystal analysis, the following crystal data:

Crystal system: monoclinic system

Space group: $P2_1$

Lattice constant:

$a = 10.3221$ (14) Å

$b = 9.8634$ (13) Å

$c = 11.6643$ (16) Å

$\alpha = 90^\circ$

$\beta = 100.317^\circ$

$\gamma = 90^\circ$

Unit lattice volume: 1169.5 (3) Å³.

5. The crystal according to any of claims 1 to 4, in an anhydrous form.

6. The crystal according to any of claims 1 to 5, having a purity of 90 % by mass or more.

7. A pharmaceutical composition comprising the crystal according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.